Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients

Lung Cancer Clinical Trial

— TELE001  

Official title:

A Prospective Study of Telephonic Contact and Subsequent Physical Follow up of Radically Treated Lung Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01133067
• Other study ID #: PROJECT NO 754
• Status: Completed
• Start date: July 2010
• Est. completion date: July 2016

Study information

• Verified date: November 2017
• Source: Tata Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Does the routine clinical practice of follow up after primary treatment in lung cancer patients has any utility.

Description:

Patients of cancer, after their primary treatment are subsequently called for follow up visits to assess the disease status. This has two important implications from the point of view of resource management. One, patients often have to travel long distances to report to the hospital and have to take care of other logistics such as their accommodation, local travel and food. Further often the patient travels with 1-2 attendants which adds to the logistic burden. Also, these patients of follow up also contribute to the load on existing hospital services. Many authors have speculated that follow-up visits generate anxiety about possible disease recurrence. On the other hand, many others have suggested that although there may be a transient increase in anxiety, patients are ultimately reassured by this practice. Hence, there is no firm evidence for the practice and the need for follow up in oncology care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. All patients of lung cancer treated with a radical aim (e.g surgery, Chemoradiation, surgery followed by adjuvant treatment or any other combination)

2. Patients should have completed radical /adjuvant treatment, if any

3. Patients of both SCLC and NSCLC

4. Patients with at least two telephone numbers (landline/mobile/both)

5. Patients willing to participate

Exclusion Criteria:

1. All patients for palliative intention

2. Patients with less than two contact telephone numbers -

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
India	Tata Memorial Hospital	Mumbai	MS

Sponsors (1)

Lead Sponsor	Collaborator
Tata Memorial Hospital

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concurrence Between the Telephonic Interview and the Physician Assessment	The Prevalence and bias adjusted Kappa (PABAK) score for concurrence between telephonic and physician assessment of disease status of each patient at each follow up visit was analysed.	2 years
Secondary	Cost Analysis	On average, each patient spent INR 5117.10 on travel and INR 3079.06 on lodging per follow up visit.	2 years